Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $33.57.
A number of equities research analysts recently commented on the stock. Truist Financial began coverage on shares of Summit Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $35.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of Summit Therapeutics in a report on Wednesday, December 11th. They set an “overweight” rating and a $30.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Summit Therapeutics in a research note on Tuesday, January 21st. JMP Securities started coverage on shares of Summit Therapeutics in a research note on Monday, November 4th. They issued a “market outperform” rating and a $32.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Summit Therapeutics in a report on Friday, December 6th. They set a “buy” rating and a $31.00 target price on the stock.
Read Our Latest Report on Summit Therapeutics
Institutional Investors Weigh In On Summit Therapeutics
Summit Therapeutics Price Performance
NASDAQ SMMT opened at $21.50 on Thursday. Summit Therapeutics has a one year low of $2.10 and a one year high of $33.89. The business’s fifty day moving average is $19.15 and its 200-day moving average is $17.83. The stock has a market capitalization of $15.86 billion, a price-to-earnings ratio of -76.78 and a beta of -0.87.
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). During the same period last year, the company earned ($0.03) EPS. Research analysts expect that Summit Therapeutics will post -0.3 EPS for the current fiscal year.
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Featured Articles
- Five stocks we like better than Summit Therapeutics
- How to Capture the Benefits of Dividend Increases
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Why Invest in High-Yield Dividend Stocks?
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- What Are Treasury Bonds?
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.